Table 1 Patients characteristics (n = 32)
Characteristics | Number (rate%) | |
|---|---|---|
Age | 50-59 | 9 (28 %) |
60-64 | 6 (19 %) | |
65-69 | 8 (25 %) | |
70+ | 9 (28 %) | |
Side | Left | 14 (44 %) |
Right | 18 (56 %) | |
Tumor site | Upper inner quadrant | 12 (38 %) |
Lower inner quadrant | 1 (3 %) | |
Upper outer quadrant | 16 (50 %) | |
Lower outer quadrant | 2 (6 %) | |
Central portion | 1 (3 %) | |
Pathological size | Tis | 3 (9 %) |
<1 cm | 13 (41 %) | |
1-2 cm | 15 (47 %) | |
>2 cm | 1 (3 %) | |
Positive nodes | None | 28 (88 %) |
1 | 4 (13 %) | |
Tumor grades | G1, 2 | 28 (88 %) |
G3 | 4 (13 %) | |
Hormone receptor | ER+ and/or PgR+ | 29 (91 %) |
ER- and PgR- | 3 (9 %) | |
HER2 status | Positive | 3 (9 %) |
Negative | 29 (91 %) | |
Molecular subtype | Luminal A | 27 (84 %) |
Luminal B | 2 (6 %) | |
HER2 positive (non-luminal) | 1 (3 %) | |
Triple negative | 2 (6 %) | |
ASTRO consensus statement categories for the application of APBI | suitable | 16 (50 %) |
cautionary | 12 (38 %) | |
unsuitable | 4 (13 %) | |
Adjuvant systemic treatment | None | 5 (16 %) |
Endocrine therapy | 22 (69 %) | |
Chemotherapy | 3 (9 %) | |
Endocrine and Chemotherapy | 2 (6 %) | |